ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RPRX • GB00BMVP7Y09

44.8499 USD
+0.75 (+1.7%)
Last: Feb 6, 2026, 11:53 AM
Fundamental Rating

6

Taking everything into account, RPRX scores 6 out of 10 in our fundamental rating. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are some minor concerns on its financial health. RPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year RPRX was profitable.
  • RPRX had a positive operating cash flow in the past year.
  • Each year in the past 5 years RPRX has been profitable.
  • RPRX had a positive operating cash flow in each of the past 5 years.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

  • RPRX's Return On Assets of 3.95% is amongst the best of the industry. RPRX outperforms 84.82% of its industry peers.
  • Looking at the Return On Equity, with a value of 11.93%, RPRX belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 6.43%, RPRX belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
  • RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.87%.
  • The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROIC 6.43%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • With an excellent Profit Margin value of 32.55%, RPRX belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
  • RPRX's Profit Margin has declined in the last couple of years.
  • RPRX has a better Operating Margin (65.22%) than 100.00% of its industry peers.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.22%
PM (TTM) 32.55%
GM N/A
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
  • Compared to 1 year ago, RPRX has less shares outstanding
  • Compared to 5 years ago, RPRX has more shares outstanding
  • RPRX has a worse debt/assets ratio than last year.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • RPRX has an Altman-Z score of 1.81. This is not the best score and indicates that RPRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of RPRX (1.81) is comparable to the rest of the industry.
  • RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 9.47, RPRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
  • RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 75.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Altman-Z 1.81
ROIC/WACC0.73
WACC8.77%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

  • RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • RPRX has a Current ratio (3.48) which is in line with its industry peers.
  • RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • RPRX has a Quick ratio (3.48) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.24% over the past year.
  • The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
  • Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
  • Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.53% on average over the next years. This is quite good.
  • RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.65% yearly.
EPS Next Y17.31%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year17.2%
Revenue Next 2Y9.47%
Revenue Next 3Y8.62%
Revenue Next 5Y10.65%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.91, the valuation of RPRX can be described as reasonable.
  • Based on the Price/Earnings ratio, RPRX is valued cheaply inside the industry as 90.58% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (27.67), we can say RPRX is valued rather cheaply.
  • A Price/Forward Earnings ratio of 8.64 indicates a reasonable valuation of RPRX.
  • Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 91.10% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 27.20. RPRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.91
Fwd PE 8.64
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 82.72% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.4
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RPRX may justify a higher PE ratio.
  • A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.63
PEG (5Y)N/A
EPS Next 2Y12.49%
EPS Next 3Y13.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • RPRX has a Yearly Dividend Yield of 2.30%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.61, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.19% of the companies listed in the same industry.
  • RPRX's Dividend Yield is a higher than the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.3%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/6/2026, 11:53:04 AM)

44.8499

+0.75 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-11
Inst Owners81.5%
Inst Owner Change-1.67%
Ins Owners1.56%
Ins Owner Change6.8%
Market Cap25.89B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target46.34 (3.32%)
Short Float %7.09%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 2.3%
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0%
PT rev (3m)4.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.79%
EPS NY rev (1m)0%
EPS NY rev (3m)5.1%
Revenue NQ rev (1m)-0.89%
Revenue NQ rev (3m)3.65%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)2.75%
Valuation
Industry RankSector Rank
PE 10.91
Fwd PE 8.64
P/S 11.02
P/FCF 27.4
P/OCF 10.76
P/B 4.04
P/tB 4.72
EV/EBITDA N/A
EPS(TTM)4.11
EY9.16%
EPS(NY)5.19
Fwd EY11.57%
FCF(TTM)1.64
FCFY3.65%
OCF(TTM)4.17
OCFY9.29%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.63
PEG (5Y)N/A
Graham Number32.06
Profitability
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROCE 8.15%
ROIC 6.43%
ROICexc 7.12%
ROICexgc 7.53%
OM 65.22%
PM (TTM) 32.55%
GM N/A
FCFM 40.2%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 62.15%
Interest Coverage -5.67
Cash Conversion N/A
Profit Quality 123.5%
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z 1.81
F-Score5
WACC8.77%
ROIC/WACC0.73
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year17.2%
Revenue Next 2Y9.47%
Revenue Next 3Y8.62%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.91 and the Price/Book (PB) ratio is 4.04.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 49.36%.